NCT04991480
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: BRCA+
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1|Phase 2
Drug Category: Misc Inhibitor

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: All breast cancer patients are eligible for this study, but patients with HER2-negative metastatic breast cancer & a germline (hereditary) BRCA 1/2 mutation are eligible for Part B3
Exclusions: For Part B3, patients with more than 3 prior chemotherapy-inclusive regimens (including antibody conjugates or with prior treatment of a PARP inhibitor (e.g. Lynparza/olaparib, Talzenna/talazoparib); Patients with symptomatic or uncontrolled brain metastases or leptomeningeal disease requiring concurrent treatment – see trial for details; Patients with inflammatory breast cancer
https://ClinicalTrials.gov/show/NCT04991480